Point72 Asset Management, L.P. 13D and 13G filings for CytomX Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 5:30 pm Sale | 2025-06-30 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 8,084,623 5.100% | -5,009,777 (-38.26%) | Filing |
| 2025-05-14 5:14 pm Purchase | 2025-05-12 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 13,094,400 8.300% | 13,094,400 (New Position) | Filing |
| 2023-02-14 4:13 pm Sale | 2022-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 0 0.000% | -6,312,371 (Position Closed) | Filing |
| 2022-02-14 4:43 pm Purchase | 2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 6,312,371 9.700% | 788,465 (+14.27%) | Filing |
| 2021-01-26 5:20 pm Purchase | 2021-01-25 | 13G | CytomX Therapeutics, Inc. CTMX | Point72 Asset Management, L.P. | 5,523,906 9.100% | 5,523,906 (New Position) | Filing |